Hot-melt extrusion promotes dissolution, extends “spring-parachute” process and inhibits crystallization in supersaturating microparticle systems
Source abstract
Abstract
Despite the potential advantages of amorphism-induced supersaturation, the merit of new amorphization formation methods on the properties of the amorphous drug including the stability of the amorphous state, dissolution/solubility, supersaturation, and “spring-parachute” process is still poorly understood, particularly for certain amorphous supersaturating drug delivery systems (aSDDS). The present work aimed to explore the detailed merit of current attractive amorphization manufacturing methods (i. g., hot-melt extrusion (HME) technique) on the property improvement of aSDDS in form of amorphous solid dispersion microparticles by employing a model BCS II drug nitrendipine and a polyvinylpyrrolidone-based model polymer copovidone. Many aSDDS systems were developed by various methods, and their physicochemical properties were characterized by SEM, PXRD and DSC. HME-triggered amorphization induced superior supersaturation by the observation of the highest dissolution and solubility. HME induced the optimal supersaturation duration by the observed greatest extension of “spring-parachute” process (e. g., maximum AUC spring-parachute ). HME technique is comparable with other techniques for the stabilization of amorphous state during storage. All aSDDS systems by HME and other methods showed improved long-term stability of the amorphous state in comparison to the pure amorphous drug. Fourier transformation infrared spectroscopy, Noyes-Whitney equation, nucleation theory and Gibbs free energy of transfer ( Δ G t o ) were used to analyze the underlying mechanisms. Molecular mechanism studies indicated that HME caused a stronger crystallization inhibition effect in the aSDDS systems than other methods, but molecular interaction is not a dominant mechanism for property enhancement caused by HME. For the mechanism associated with the polymer itself (PVPVA64), it could inhibit the drug recrystallization, solubilize the drug spontaneously and cause the improved molecular interactions in all aSDDS systems. This study provided a deep insight into detailed advantage of HME-triggered supersaturation/amorphization and facilitated the applications of the technique both in the field of particuology and in pharmaceutical industry.
Source: expertdata · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Drug Solubulity and Delivery Systems · Crystallization and Solubility Studies · Advanced Drug Delivery Systems
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (38)
Show source-provided references
1. Self-emulsifying drug delivery system: Mucus permeation and innovative quantification technologies10.1016/j.addr.2019.04.001 ↗
2. Supersaturating drug delivery systems: Fast is not necessarily good enough10.1002/jps.22750 ↗
3. Coupling hot melt extrusion and fused deposition modeling: Critical properties for successful performance10.1016/j.addr.2021.02.006 ↗
4. Supersaturating drug delivery systems: The answer to solubility-limited oral bioavailability10.1002/jps.21650 ↗
5. Crystallization tendency of active pharmaceutical ingredients following rapid solvent evaporation-classification and comparison with crystallization tendency from undercooled melts10.1002/jps.22214 ↗
6. Pharmacokinetics and pharmacodynamics of nitrendipine in healthy subjects and patients with kidney and liver disease10.1097/00005344-198806124-00003 ↗
7. Preparation and evaluation of solid dispersion of atorvastatin calcium with Soluplus® by spray drying technique10.1248/cpb.c14-00030 ↗
8. Nicardipine, nitrendipine and bepridil: New calcium antagonists for cardiovascular disorders
9. Preparation and drug delivery of dextran-drug complex10.1080/10717544.2019.1580322 ↗
10. Enhanced oral bioavailability and anti-echinococcosis efficacy of albendazole achieved by optimizing the “spring” and “parachute”10.1021/acs.molpharmaceut.9b00851 ↗
11. Thermodynamic aspects of the preparation of amorphous solid dispersions of Naringenin with enhanced dissolution rate10.1016/j.ijpharm.2020.119363 ↗
12. An enteric polymer mitigates the effects of gastric pH on oral absorption of poorly soluble weak acid drugs from supersaturable formulations: A case study with dantrolene10.1016/j.ejpb.2020.07.032 ↗
13. Raman imaging of amorphous-amorphous phase separation in small molecule co-amorphous systems10.1016/j.ejpb.2020.08.007 ↗
14. Development and evaluation of nitrendipine loaded solid lipid nanoparticles: Influence of wax and glyceride lipids on plasma pharmacokinetics10.1016/j.ijpharm.2006.11.004 ↗
15. Tailoring supersaturation from amorphous solid dispersions10.1016/j.jconrel.2018.04.014 ↗
16. Molecular interactions in posaconazole amorphous solid dispersions from two-dimensional solid-state NMR spectroscopy10.1021/acs.molpharmaceut.9b00174 ↗
17. Hybrid drug nanocrystals10.1016/j.addr.2019.06.006 ↗
18. Influence of process and formulation parameters on dissolution and stability characteristics of Kollidon® VA 64 hot-melt extrudates10.1208/s12249-014-0226-4 ↗
19. Impact of polymer type on bioperformance and physical stability of hot melt extruded formulations of a poorly water-soluble drug10.1016/j.ijpharm.2016.03.036 ↗
20. Antihypertensive therapy with the long-acting calcium antagonist nitrendipine
21. Physicochemical and pharmacokinetic characterization of amorphous solid dispersion of meloxicam with enhanced dissolution property and storage stability, AAPS
22. Amorphous solid dispersions: An update for preparation, characterization, mechanism on bioavailability, stability, regulatory considerations, and marketed products10.1016/j.ijpharm.2020.119560 ↗
23. Comparison of induction methods for supersaturation: Amorphous dissolution versus solvent shift10.1016/j.ejpb.2020.04.017 ↗
24. Nitrendipine nanocrystals: Its preparation, characterization, and in vitro-in vivo evaluation, AAPS10.1208/s12249-011-9682-2 ↗
25. Hybridized nanoamorphous micellar dispersion using a QbD-DM3 linked rational product design strategy for ritonavir: A BCS IV drug10.1016/j.ijpharm.2020.119727 ↗
26. Screening of drug-sericin solid dispersions for improved solubility and dissolution10.1016/j.ijbiomac.2017.10.035 ↗
27. An exploratory pilot analysis of the optimal pellet number in 100 mg of itraconazole capsule to maximize the surface area to satisfy the Noyes-Whitney equation
28. Stability assessment of Hypromellose acetate succinate (HPMCAS) NF application in hot melt extrusion (HME)10.1016/j.carbpol.2013.09.017 ↗
29. Mechanisms of increased bioavailability through amorphous solid dispersions: A review10.1080/10717544.2019.1704940 ↗
30. Theoretical analysis of drug dissolution: I. Solubility and intrinsic dissolution rate10.1016/j.xphs.2015.12.006 ↗
31. Intelligent “peptide-gathering mechanical arm” tames wild “Trojan-Horse” peptides for the controlled delivery of cancer nanotherapeutics10.1021/acsami.7b15523 ↗
32. Microarray plate method for estimation of precipitation kinetics of celecoxib under biorelevant conditions and precipitate characterization10.1021/acs.molpharmaceut.8b00267 ↗
33. Specific mechanical energy - an essential parameter in the processing of amorphous solid dispersions10.1016/j.addr.2021.03.006 ↗
34. Rate of nucleation in condensed systems10.1063/1.1747055 ↗
35. Amorphous solid dispersions: Rational selection of a manufacturing process10.1016/j.addr.2016.01.012 ↗
36. Polymorphs and amorphous state of glipizide: Preparation and solid-state transformations10.1016/j.xphs.2020.10.063 ↗
37. Drug precipitation inhibitors in supersaturable formulations10.1016/j.ijpharm.2013.05.013 ↗
38. Modeling of disintegration and dissolution behavior of mefenamic acid formulation using numeric solution of Noyes-Whitney equation with cellular automata on microtomographic and algorithmically generated surfaces10.3390/pharmaceutics10040259 ↗